Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Parsaclisib + Retifanlimab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Parsaclisib | INCB050465|INCB 50465|INCB-50465|INCB50465|WHO 10589 | PIK3CD inhibitor 26 | Parsaclisib (INCB050465) inhibits PI3K-delta, blocking activation of AKT signaling pathway and leading to apoptosis of PIK3CD expressing tumor cells (PMID: 31749910). | |
Retifanlimab | MGA 012|INCMGA00012|MGA012 | Immune Checkpoint Inhibitor 151 PD-L1/PD-1 antibody 98 | Retifanlimab (INCMGA00012) is a humanized IgG4 monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT085). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03589651 | Phase I | Parsaclisib + Retifanlimab Epacadostat + Retifanlimab | INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | Active, not recruiting | USA | 0 |